Bone protection by inhibition of microRNA-182

Area of Science:

• Molecular Biology
• Immunology
• Skeletal Biology

Background:

• MicroRNAs (miRNAs) show therapeutic potential but are underexplored for skeletal diseases like osteoporosis and rheumatoid arthritis (RA).
• Osteolysis, characterized by excessive bone resorption, is a hallmark of these conditions.
• Targeting key regulators of osteoclastogenesis is crucial for developing effective treatments.

Purpose of the Study:

• To identify microRNAs involved in osteoclastogenesis and bone homeostasis.
• To investigate the therapeutic potential of targeting specific microRNAs for skeletal diseases.
• To elucidate the molecular mechanisms underlying miR-182's role in bone diseases.

Main Methods:

• Generated myeloid-specific miR-182 knockout mice.
• Utilized mouse models of ovariectomy-induced osteoporosis and inflammatory arthritis.
• Administered miR-182 inhibitors pharmacologically.
• Performed mechanistic studies to identify miR-182 targets and signaling pathways.

Main Results:

• miR-182 was identified as a key regulator of osteoclastogenesis.
• Deletion of miR-182 protected against excessive bone resorption in disease models.
• miR-182 inhibitors suppressed pathologic bone erosion.
• PKR (protein kinase double-stranded RNA-dependent) was identified as a direct miR-182 target, inhibiting osteoclastogenesis via an IFN-β autocrine loop.
• miR-182, PKR, and IFN-β levels were altered in RA patients and correlated with monocyte osteoclastogenic capacity.

Conclusions:

• The miR-182-PKR-IFN-β axis is a novel regulatory network in osteoclastogenesis.
• Targeting miR-182 offers a promising therapeutic strategy for preventing bone loss in osteoporosis and RA.
• Pharmacological inhibition of miR-182 demonstrates significant osteoprotective effects.